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Objectives This study investigated the impact of procedural success on mortality following chronic
total occlusion (CTO) percutaneous coronary intervention (PCI) in a large cohort of patients in the
drug-eluting stent era.
Background Despite advances in expertise and technologies, many patients with CTO are not of-
fered PCI.
Methods A total of 6,996 patients underwent elective PCI for stable angina at a single center (2003
to 2010), 836 (11.9%) for CTO. All-cause mortality was obtained to 5 years (median: 3.8 years; inter-
quartile range: 2.0 to 5.4 years) and stratiﬁed according to successful chronic total occlusion (sCTO)
or unsuccessful chronic total occlusion (uCTO) recanalization. Major adverse cardiac events (MACE)
included myocardial infarction (MI), urgent revascularization, stroke, or death.
Results A total of 582 (69.6%) procedures were successful. Stents were implanted in 97.0% of suc-
cessful procedures (mean: 2.3  0.1 stents per patient, 73% drug-eluting). Prior revascularization
was more frequent among uCTO patients: coronary artery bypass grafting (CABG) (16.5% vs. 7.4%;
p  0.0001), PCI (36.0% vs. 21.2%; p  0.0001). Baseline characteristics were otherwise similar. In-
traprocedural complications, including coronary dissection, were more frequent in unsuccessful
cases (20.5% vs. 4.9%; p  0.0001), but did not affect in-hospital MACE (3% vs. 2.1%; p  NS). All-
cause mortality was 17.2% for uCTO and 4.5% for sCTO at 5 years (p  0.0001). The need for CABG
was reduced following sCTO (3.1% vs. 22.1%; p  0.0001). Multivariate analysis demonstrated that
procedural success was independently predictive of mortality (hazard ratio [HR]: 0.32 [95% conﬁ-
dence interval (CI): 0.18 to 0.58]), which persisted when incorporating a propensity score (HR: 0.28
[95% CI: 0.15 to 0.52]).
Conclusions Successful CTO PCI is associated with improved survival out to 5 years. Adoption of
techniques and technologies to improve procedural success may have an impact on
prognosis. (J Am Coll Cardiol Intv 2012;5:380–8) © 2012 by the American College of Cardiology
Foundation
From the *Department of Cardiology, Barts and the London NHS Trust, London, United Kingdom; †Department of Clinical
Pharmacology, William Harvey Research Institute, Queen Mary University, London, United Kingdom; ‡NIHR Cardiovascular
Biomedical Research Unit, London Chest Hospital, London, United Kingdom; and the §Yale University Department of
Cardiology, New Haven, Connecticut. Prof. Rothman is professor of interventional cardiology at Barts and the London NHS Trust
and has been Vice-President of Medical Affairs Coronary and Renal Denervation for Medtronic since January 2010. He is also an
employee of Medtronic. Dr. Thompson is a consultant for BridgePoint Medical, Abbott Vascular, and Terumo; and has equity in
BridgePoint Medical. All other authors have stated that they have no relationships relevant to the contents of this paper to disclose.Manuscript received October 30, 2011; revised manuscript received December 23, 2011, accepted January 5, 2012.
s
a
l
t
p
c
t
e
i
M r
i
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 4 , 2 0 1 2 Jones et al.
A P R I L 2 0 1 2 : 3 8 0 – 8 Successful CTO PCI Improves Long-Term Survival
381Percutaneous treatment of chronic total occlusion (CTO)
remains a challenge. Despite being commonly encountered
in patients undergoing coronary angiography (1,2), recana-
lization of a CTO is attempted in only 10% to 15% of
patients undergoing percutaneous coronary intervention
(PCI) (3). CTO PCI procedures may be lengthy and
complex, with elevated radiation exposure, increased con-
trast load, lower procedural success rate, and a higher risk of
See page 389
complication when compared with non-CTO elective PCI
(4,5). Moreover, there is uncertainty as to the prognostic
impact of percutaneous CTO revascularization. Patients
with chronically occluded single-vessel disease are often
managed medically regardless of the severity of symptoms
and extent of ischemia, as the anatomy is deemed to be
stable. Meanwhile, those with multivessel disease involving
a CTO may be referred for bypass graft surgery even if other
lesions are suitable for PCI (1,6).
Data from small cohorts in the pre–drug-eluting stent
(DES) era do not give a clear picture, with some indicating
that successful CTO PCI may improve left ventricular function
and survival when compared with failed CTO PCI (7–9), and
some not (10,11). A more recent multicenter registry does
uggest that successful CTO PCI decreases cardiac mortality, with
reduced requirement for bypass surgery (12). Clarifying the
ong-term clinical outcomes of CTO PCI is therefore important
o justify potential investments in training and technology, and the
otential risks involved.
In the present study, we report outcomes from a large
ohort of consecutive patients undergoing PCI for CTO in
he DES era. The main aim of the study was to assess the
ffect of procedural success on long-term outcome (mortal-
ty, further revascularization).
ethods
Study population. A total of 7,713 consecutive patients
underwent elective PCI for stable angina at a single high-
volume cardiac center in London, United Kingdom, from
October 2003 to May 2010; 6,996 (91%) had completed
database records and National Health Service (NHS) num-
bers, and were included in the analysis. Eight hundred
thirty-six (11.9%) procedures were performed for CTOs
(Fig. 1). A CTO was defined as a complete obstruction of
the vessel with Thrombolysis In Myocardial Infarction
(TIMI) flow grade 0 and an estimated duration of 3
months (13,14). Patients undergoing an initial unsuccessful
procedure but undergoing a subsequent successful attempt
were classified as successful. Data were prospectively entered
into a clinical database at the time of the PCI by the
performing physician. Data collected included patient char-
acteristics (age, previous myocardial infarction [MI]/PCI/coronary artery bypass grafting [CABG], hypertension,
diabetes mellitus, hypercholesterolemia, peripheral vascular
disease, New York Heart Association functional class,
smoking status, chronic renal failure [CRF]: creatinine
200 mol/l or on renal replacement therapy, left ventric-
ular function, and cardiogenic shock) and procedure-related
data (indications for PCI, target vessel, number of diseased
vessels, use of intravascular ultrasound/pressure wire, use of
DES and glycoprotein [GP] IIb/IIIa inhibitor). The group
of patients excluded from the study due to incomplete data
entry or absent NHS number contained a similar proportion
of CTOs as the study population (9.9%).
A total of 19 individual senior
interventional cardiologists per-
formed CTO procedures. All
patients were pre-treated with
aspirin and clopidogrel (a load-
ing dose of 300 to 600 mg be-
fore the procedure). After the
procedure, all patients were
given aspirin indefinitely and
either clopidogrel 75 mg daily
for at least 4 weeks after im-
plantation of bare-metal stents
(BMS), or for at least 12 months
after implantation of a DES. DES
used included sirolimus-eluting
stents, paclitaxel-eluting stents,
zotarolimus-eluting stents, and
everolimus-eluting platforms. GP
IIb/IIIa inhibitors were given at
the discretion of the operator. All
CTO interventions were per-
formed via an antegrade approach.
A successful PCI was defined as
final TIMI flow grade 2 and a
esidual stenosis 30% after stent
mplantation.
Endpoints. In-hospital outcomes
recorded included in-hospital
death, Q-wave MI (new patho-
logical Q waves in the coronary
distribution of the treated artery with an increase of creatine
kinase-myocardial band to 2 times the reference value or
significant elevation in troponin T), and target vessel revas-
cularization (TVR) by both PCI and CABG. Major adverse
cardiac event (MACE) was defined as a composite of MI,
all-cause mortality, TVR, and stroke. Non-MACE compli-
cations recorded included arterial complications, aortic dis-
section, coronary dissection (dissection defined as uninten-
tional intimal disruption based on angiographic appearance
using the National Heart, Lung, and Blood Institute clas-
sification system for intimal tears [15]), side-branch occlu-
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass grafting
CI  confidence interval
CRF  chronic renal failure
CTO  chronic total
occlusion
DES  drug-eluting stent(s)
GP  glycoprotein
HR  hazard ratio
LAD  left anterior
descending coronary artery
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
NHS  National Health
Service
PCI  percutaneous
coronary intervention
sCTO  successful chronic
total occlusion
recanalization
TVR  target vessel
revascularization
uCTO  unsuccessful
chronic total occlusion
recanalizationsion, heart block, and direct current cardioversion. All-cause
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382mortality data were recorded as of September 21, 2010, and
obtained via the British Cardiovascular Intervention Soci-
ety–U.K. Central Cardiac Audit Database. This national
database is linked to the U.K. Office of National Statistics
and provides live/death status of treated patients. Only
patients who had complete database records and NHS
unique numbers (allowing live/death status to be assessed)
were included in the analysis. A retrospective data quality
audit of 100 randomly selected medical records established
that 94.8% of data fields, including complications, were
entered correctly into the database. Patient outcomes were
stratified according to successful (sCTO) or unsuccessful
Figure 1. Flow Diagram of Patients Treated by PCI
Patients were treated between October 2003 and May 2010. The ﬂowchart
describes patient exclusions and make-up of study population. BCIS  Brit-
ish Cardiovascular Intervention Society; CTO  chronic total occlusion;
NHS  National Health Service; ONS  Ofﬁce National Statistics; PCI  per-
cutaneous coronary intervention.(uCTO) CTO recanalization. Long-term TVR procedures hwere identified from the interventional database, surgical da-
tabase, and the patients’ electronic clinical records. All surgical
revascularization procedures following PCI were identified
from the cardiac surgical database.
Ethics. The data were collected as part of a national cardiac
audit, and all patient identifiable fields were removed before
analysis. The local ethics committee confirmed that formal
ethical approval was not required.
Statistical analysis. Clinical characteristics of CTO patients
reated successfully versus unsuccessfully, and CTO PCI
ersus non-CTO PCI were compared using the Pearson
hi-square test for categorical variables and Student t test for
ontinuous variables. We calculated Kaplan-Meier product
imits for cumulative probability of reaching an endpoint
nd used the log-rank test for evidence of a statistically
ignificant difference between the groups. Time was mea-
ured from the first admission for a procedure to outcome
all-cause mortality). Cox regression analysis was used to
stimate hazard ratios (HRs) for the effect of procedural
uccess in age-adjusted and fully adjusted models, based on
ovariates (p  0.05) associated with the outcome. A
ropensity score analysis was carried out using a nonparsi-
onious logistic regression model comparing successful and
nsuccessful procedures (16). Model discrimination (C-
tatistic) was assessed using the area under the receiver-
perating characteristic curve. Multiple variables were in-
luded in the model, including all variables with significant
nteractions. We then undertook a regression adjustment
ncorporating the propensity score into a proportional haz-
rd model as a covariate. We used SPSS for Mac version
8.0 (IBM, Armonk, New York) for all analyses.
esults
Of the 836 procedures undertaken, 582 (69.6%) of the
CTO PCIs were successful. Follow-up data were obtained
out to 5 years (median: 3.8 years [interquartile range: 2.0 to
5.4 years]). Of the 582 that were successful, 570 (97.9%)
were successful at first attempt, and 12 (2.1%) were success-
ful at a subsequent attempt.
Patient characteristics. Baseline characteristics stratified ac-
cording to successful versus unsuccessful CTO PCI are
demonstrated in Table 1. Characteristics of 6,160 stable
patients undergoing a PCI for non-CTO lesions during the
same period are included for comparison. Previous revascu-
larization with both PCI and CABG was more frequent
among patients with uCTO versus sCTO PCI. There were
similar mean ejection fractions in the 2 groups, but there
was a higher number of patients with an ejection fraction
40% in the unsuccessful group. Demographics were oth-
erwise similar between these groups.
Procedural characteristics. Four hundred fifty-one patients
53.9%) had single-vessel disease, with 385 patients (46.1%)
aving multivessel disease (Table 2). Six hundred sixty-one
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383(79.1%) patients underwent single-vessel PCI, with the
remainder undergoing CTO PCI as part of a multivessel
procedure at the same sitting. Of those with multivessel
disease undergoing successful initial single-vessel CTO PCI
Table 1. Baseline Characteristics According to Proce
Variable
sCTO
(n  582)
uC
(n 
Age, yrs 62.37 11.5 63.7
Female 141 (24.3) 53 (
Caucasian 352 (60.5) 150 (
Hypertension 372 (63.9) 169 (
Diabetes mellitus 157 (27.0) 73 (
Hypercholesterolemia 327 (56.1) 156 (
Previous MI 185 (31.8) 92 (
Previous CABG 43 (7.4) 42 (
Previous PCI 123 (21.2) 91 (
Severe angina 264 (45.4) 116 (
LVEF 55.6 9.2 53.5
EF  40% 22 (3.8) 18 (
CRF (creatinine 200) mol/l 14 (2.4) 4 (
PVD 14 (2.4) 8 (
Previous CVA 6 (1.0) 3 (
Values are mean SD or n (%).
CABG coronary artery bypass grafting; CRF chronic renal failure;
fraction; LVEF left ventricular ejection fraction; MImyocardial infa
disease; sCTO successful chronic total occlusion recanalization; uCT
Table 2. Procedural Characteristics According to Procedural Success
sCTO
(n  582) (n
Arterial access site
Radial 125 (21.5)
Femoral 424 (72.9) 1
Dual site (radial/femoral or bilateral femoral) 23 (3.9)
Brachial 10 (1.7)
Single-vessel disease 321 (55.2) 1
Multivessel disease 261 (44.8) 1
2-vessel 164 (28.1)
3-vessel 97 (16.7)
Single-vessel intervention 448 (77.0) 2
Average vessels treated 1.32 0.75 1
CTO vessel
Right coronary artery 192 (42.9) 1
Left anterior descending 168 (37.5)
Left circumﬂex coronary artery 77 (13.2)
Saphenous vein graft 11 (1.9)
Stent deployed 565 (97.0)
No. of stents used 2.31 1.5
DES 430 (76.1)
IVUS 25 (4.3)
Glycoprotein IIb/IIa inhibitor 252 (43.3)
Values are n (%) or mean SD.DES drug-eluting stent(s); IVUS intravascular ultrasound; NA not applicable; other abbreviations(n  210), 53 (25.2%) underwent staged treatment and 162
74.8%) medical therapy for the remaining disease on the
asis of symptoms and burden of ischemia. Of those
ndergoing single-vessel intervention, CTO PCI was per-
Success
p Value
Non-CTO PCI
(n  6,160)
p Value
(sCTO vs. non-CTO)
0.113 63.2 10.9 0.201
0.267 1,709 (27.7) 0.077
0.482 4,441 (72.1) 0.0001
0.456 3,326 (54.0) 0.0001
0.632 1,681 (27.3) 0.909
0.183 3,057 (49.6) 0.0029
0.231 1,161 (18.8) 0.0001
0.0001 433 (7.0) 0.811
0.0001 1,289 (20.9) 0.948
0.681 1,796 (29.2) 0.0001
0.074 56.0 9.2 0.419
0.032 87 (1.4) 0.0001
0.606 136 (2.2) 0.871
0.525 160 (2.6) 0.887
0.838 76 (1.2) 0.819
chronic total occlusion; CVA cerebrovascular accident; EF ejection
CI percutaneous coronary intervention; PVD peripheral vascular
successful chronic total occlusion recanalization.
4) p Value
Non-CTO PCI
(n  6,160)
p Value
(sCTO vs. non-CTO)
.8) 0.210 1,959 (31.8) 0.0001
.8) 0.654 4,176 (67.8) 0.01
) 0.500 NA
) 0.743 104 (0.17) 0.908
.2) 0.101 4,238 (68.8) 0.0001
.8) 0.292 1,922 (31.2) 0.0001
.2) 0.221 1,121 (18.2) 0.0001
.6) 0.0007 801 (13.0) 0.0001
.8) 0.0004 4,164 (67.6) 0.0001
.62 0.0015 1.26 0.53 0.019
.8) 0.0003 NA NA
.0) 0.0005 NA NA
.4) 0.615 NA NA
) 0.298 NA NA
NA 5,821 (94.5) 0.01
NA 1.73 1.1 0.0001
NA 3,843 (62.4) 0.0001
) 0.513 382 (6.2) 0.08
) 0.0001 1,558 (25.3) 0.0001dural
TO
254)
11.2
20.8)
59.0)
66.7)
28.6)
61.4)
36.4)
16.5)
36.0)
45.8)
1.4
7.1)
1.6)
3.2)
1.2)
CTO
rction; PuCTO
 25
45 (17
85 (72
18 (7.0
6 (2.4
30 (51
24 (48
64 (25
60 (23
13 (83
.19 0
06 (49
64 (30
35 (16
8 (3.7
NA
NA
NA
9 (3.5
20 (7.9as in Table 1.
c
s
(
u
y
1
0
w
i
5
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 4 , 2 0 1 2
A P R I L 2 0 1 2 : 3 8 0 – 8
Jones et al.
Successful CTO PCI Improves Long-Term Survival
384formed on the left anterior descending coronary artery
(LAD) in 232 (35.1%), left circumflex coronary artery in
112 (16.9%), and right coronary artery in 298 (45.1%)
patients. Patients in the successful group were more likely to
have undergone LAD intervention, whereas those in the
unsuccessful group were more likely to have undergone
intervention to the right coronary artery. There was no
difference in success rates for the circumflex. Radial access
was used in 20.3% of all CTO PCI cases compared with
31.8% of elective non-CTO cases (p 0.001). Dual arterial
access sites for contralateral injections were used in a low
proportion of cases, and numerically more often in unsuc-
cessful procedures, though this difference was not
significant.
Coronary stents were implanted in 565 (97.0%) of sCTO
procedures. DES were used in 430 (76.1%) cases; this was
broken down into 132 (30.9%) sirolimus-eluting stents, 178
(41.4%) paclitaxel-eluting stents, 89 (20.7%) zotarolimus-
eluting stents, and 17 (4.0%) everolimus-eluting platforms;
14 (3.3%) patients received DES of different types. GP
IIb/IIIa inhibitors were used in a relatively high proportion
of successful cases (43%), compared with 25% of all other
elective PCI cases (p  0.003).
Clinical outcomes. Procedural complications and in-hospital
MACE. Although intraprocedural complications, including
oronary dissection, perforation, no reflow, access site dis-
ection, or hematoma, were more frequent in uCTO cases
20.5% vs. 4.9%; p  0.0001), this did not have an impact
on in-hospital MACE (Table 3).
All-cause mortality. Procedural success compared with fail-
re was associated with improved all-cause mortality at 5
ears of follow-up (4.5% [95% confidence interval (CI):
Table 3. In-Hospital Outcomes and Complications Post-PCI According to
Procedural Success
sCTO
(n  582)
uCTO
(n  254) p Value
Complications
Arterial complications 6 (1.0) 2 (0.8) 0.680
Coronary dissection 12 (2.1) 33 (12.9) 0.0001
Side-branch occlusion 6 (1.0) 1 (0.4) 0.172
No/slow ﬂow 2 (0.3) 3 (1.2) 0.183
Coronary perforation 2 (0.3) 15 (5.9) 0.0001
Tamponade 0 (0.0) 1 (0.4) 0.303
In-hospital adverse events
MACE 12 (2.1) 8 (3.1) 0.393
Death 0 (0.0) 1 (0.4) 0.303
Q-wave MI 7 (1.2) 4 (1.6) 0.861
Reintervention PCI 2 (0.3) 0 (0.0) 0.765
CVA 2 (0.3) 1 (0.4) 0.303
Emergency CABG 1 (0.2) 2 (0.8) 0.576
Values are n (%).
Abbreviations as in Table 1..7% to 6.3%] vs. 17.2% [95% CI: 9.7% to 22.6%]; p .0001) (Fig. 2A). Mortality among the sCTO PCI cohort
as similar to that of patients undergoing non-CTO PCI
ndications (4.5% [95% CI: 1.7% to 6.6%] vs. 6.7% [95% CI:
.6% to 7.5%]; p  0.1) (Fig. 2B).
Target vessel revascularization. Total TVR (CABG or PCI)
at median follow-up of 3.4 years (interquartile range: 1.8 to
5.2) was 11.5% (95% CI: 5.4% to 20.2%) for successful
patients compared with 22.1% in the unsuccessful cohort
(95% CI: 15.3% to 27.5%; p  0.0001). All TVR in the
unsuccessful group was surgical. The rate of CABG in the
successful group was significantly lower (3.1% [95% CI:
0.9% to 4.4%]; p 0.0001) (Fig. 3). The majority of uCTO
patients did not undergo any subsequent revascularization
procedure.
Figure 2. Kaplan-Meier Curves Showing Cumulative Probability of
All-Cause Mortality
(A) Kaplan-Meier curves showing cumulative probability of all-cause mortal-
ity after percutaneous coronary intervention (PCI) according to procedural
success. (B) Kaplan-Meier curves showing cumulative probability of all-
cause mortality after PCI comparing chronic total occlusion (CTO) and non-
CTO PCI.
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385Successful revascularization and all-cause mortality. Over
he 5-year follow-up period, patients who were not revas-
ularized following an uCTO procedure had a substantially
orse mortality than those who underwent revascularization
ither with an initial sCTO PCI or an uCTO PCI followed
y CABG (21.4% [95% CI: 10.1% to 35.7%] vs. 4.2% [95%
I: 1.2% to 14.8%]; p  0.0001) (Fig. 4).
Predictors of mortality. Cox analysis (Table 4) revealed pro-
cedural success to be a predictor of survival compared with
procedural failure (HR: 0.27 [95% CI: 0.16 to 0.48]), and
this difference was maintained with multiple adjustment
(HR: 0.32 [95% CI: 0.18 to 0.58]). Despite the observed
increased frequency of successful recanalization in LAD
CTO cases, LAD CTO intervention per se was not
independently predictive of mortality. Although the
number of stents implanted per case was significantly
higher in CTO compared with non-CTO PCI (p 
0.0001), the use of DES versus BMS was not associated
with increased mortality at 5 years. Indeed, there was a
trend toward improved mortality (Fig. 5).
Additionally after regression adjustment incorporating
the propensity score (C-statistic: 0.78 [95% CI: 0.70 to
0.83]) into a proportional hazards model as a covariate
(calculated from age, sex, diabetes, hypertension, hyper-
cholesterolemia, previous CABG, previous PCI, previous
MI, multivessel disease, CRF, peripheral vascular disease,
cerebrovascular accident, ejection fraction, DES use, LAD
intervention, and GP IIb/IIIa use), procedural success re-
mained a predictor of survival (HR: 0.28 [95% CI: 0.15 to
Figure 3. Kaplan-Meier Curves Showing Cumulative Probability of TVR
After sCTO and uCTO PCI
LR  log-rank; PCI  percutaneous coronary intervention; sCTO  success-
ful chronic total occlusion recanalization; TVR  target vessel revasculariza-
tion; uCTO  unsuccessful chronic total occlusion recanalization.0.52]).Discussion
Our findings provide long-term follow-up data on the
largest single-center series of patients undergoing PCI for a
CTO in the DES era reported to date. These data demon-
strate that successful percutaneous CTO recanalization was
associated with improved 5-year survival, compared with a
failed procedure, sCTO and non-CTO PCI cohorts had a
similar in-hospital MACE and 5-year survival, suggesting
that long-term outcome is not significantly different for
patients undergoing successful PCI for a CTO versus a
nonoccluded stenosed vessel. The use of DES appeared to
be safe, and significantly reduced the need for subsequent
revascularization, with TVR rates commensurate with other
published series in the DES era (17,18), in comparison with
BMS.
Prior studies have described discordant results when
evaluating long-term survival following CTO PCI. Older
observational studies (14,19) including a meta-analysis (7)
have demonstrated a survival benefit if a CTO is successfully
treated; however, investigators at the Mayo Clinic reported
technical failure of CTO PCI was not associated with
increased 10-year mortality (11). The data from the present
study are consistent with the Multinational Chronic Total
Occlusion Registry (a multicenter study involving 1,791
patients at 3 centers in North America, Italy, and Korea)
(12), which also demonstrated improved long-term survival
and decreased need for bypass surgery following successful
CTO PCI. The authors report a similar rate of procedural
success, although the absolute difference in 5 year all-cause
mortality was even greater in our cohort. In particular,
uCTO PCI patients had a higher 5-year mortality in our
study than in the equivalent Multinational Registry cohort
(17.2% vs. 8.6%) despite similar demographic characteris-
Figure 4. Kaplan-Meier Curves Showing Cumulative Probability of
All-Cause Mortality After Successful RevascularizationLR  log-rank; Revasc  revascularization.
y artery;
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386tics, left ventricular function, and frequency of subsequent
CABG. This may be a consequence of longer follow-up in the
present study (median: 3.8 years [interquartile range: 2.0 to 5.4
years] vs. 2.9 years [interquartile range: 1.5 to 4.6 years]), and
completeness of follow-up with all deaths captured through the
U.K. Office of National Statistics.
As in the Multinational Registry, patients with a history
of prior revascularization had a significantly lower rate of
Table 4. Cox Proportional Hazards Model of Univaria
After PCI for CTO
Variable Comparator
Age (increase by 1 yr)
Female Male
Hypertensive Nonhypertensive
Diabetic Nondiabetic
Hyperlipidemia Nonhyperlipidemia
Previous CABG No previous CABG
Previous MI No previous MI
Previous PCI No previous PCI
Multiple CTO Single CTO
EF 40% EF 40%
Creatinine 200 mol/l Creatinine 200 m
DES BMS
LAD intervention Non-LAD intervention
Success Failure
Values are hazard ratios (95% confidence interval). *Adjusted for age,
BMS bare-metal stent(s); LAD left anterior descending coronar
Figure 5. Adjusted HRs of the Cox Analysis for All-Cause Mortality
After PCI
95% conﬁdence intervals are given. CABG  coronary artery bypass
grafting; CRF  chronic renal failure; EF  ejection fraction; HR  haz-
ard ratio; MI  myocardial infarction; PCI  percutaneous coronary
intervention.procedural success and in turn a worse clinical outcome.
This is perhaps not unexpected in the case of previous
bypass surgery patients, where vessels may have been oc-
cluded for a longer duration, and over long segments, both
of which have traditionally been associated with lower
success rates using a simple antegrade wire escalation
approach.
In recent years, a number of technological advances
and procedural developments have increased the success
of PCI for CTOs (7,20). These include retrograde wiring
through collateral channels and both antegrade and
retrograde subintimal dissection and re-entry techniques.
Emerging data from specialist CTO groups in the United
States (approximately 90% technical success, 2% MACE)
(21), Europe (approximately 83.4% technical success, 2%
MACE) (22), and Japan (J group) (approximately 86.6%
technical success, 2.3% MACE) (23) show that success rates of
80% to 90% are consistently achievable in experienced hands
with a safety profile comparable to standard risk-adjusted PCI.
Importantly, procedural success is associated with operator
volume (21). In our cohort, 19 individual operators performed
CTO procedures during the study period. It is therefore
conceivable that a smaller group of high-volume, designated
CTO-specific operators may have achieved a higher procedural
success rate.
Avoiding CTO revascularization, therefore, on the basis of
real or perceived poor success rates, unclear patient benefits,
adverse outcomes, time and resource use, or need for coronary
bypass surgery may no longer be valid in view of the high
success rate and low complication rate in experienced centers
(24). Our data add to the growing evidence base that sCTO is
Multivariate Analysis of Predictors of Mortality
Univariate
(Age Adjusted) Multivariate*
1.08 (1.05–1.12) 1.08 (1.05–1.12)
1.41 (0.69–2.91) NA
1.31 (0.75–2.29) NA
1.08 (0.57–2.03) NA
1.11 (0.63–1.90) NA
2.31 (1.12–4.77) 1.95 (0.91–4.10)
1.84 (1.06–3.21) 1.35 (0.73–2.48)
1.21 (0.63–2.33) NA
1.20 (0.38–3.98) NA
7.63 (3.50–16.64) 3.05 (1.27–7.31)
4.88 (1.51–15.78) 4.62 (1.36–12.36)
0.62 (0.25–1.50) NA
0.78 (0.44–1.36) NA
0.27 (0.16–0.48) 0.32 (0.18–0.58)
s MI, previous CABG, CRF, and EF40%.
NA not applicable; other abbreviations as in Tables 1 and 2.te and
ol/l
previouassociated with improved survival.
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387Study limitations. As with all observational registry studies,
his study was open to selection bias. Although procedural
uccess using solely an antegrade wire escalation strategy
as reassuringly high at just under 70%, this may simply
mply that more complex patients were excluded from
ercutaneous revascularization at the outset. Selection bias
ay also have impacted upon surgical revascularization
ollowing uCTO PCI. It is possible that older patients with
oor left ventricular function and previous bypass surgery
ay not have been deemed eligible for further CABG.
Other limitations include the ability to analyze only 91%
f individuals who had PCI during this period due to
bsence of a complete dataset or NHS number, although the
xcluded group of patients included a similar proportion of
TOs as the study population. Finally, as we report
ll-cause mortality rather than cardiac death specifically, it is
ossible that other disease processes could have affected
utcome.
As mentioned previously, and as with similar reports,
CTO PCI has been used as a surrogate for medical therapy.
owever, a randomized trial is required to truly test whether
TO PCI provides prognostic benefit when compared with
ontemporary optimal medical therapy alone. The Euro CTO
European Study on the Utilisation of Revascularization versus
ptimal Medical Therapy for the Treatment of Chronic Total
cclusions) trial will attempt to address precisely this issue
25). This is a study randomizing patients with stable angina
nd documented evidence of ischemia or viability in the
erritory supplied by the CTO, to either PCI or optimal
edical therapy. The primary endpoint is death and nonfatal
I over a 36-month follow-up period.
onclusions
Successful CTO PCI is associated with improved survival
out to 5 years following intervention. These data suggest
that adoption of techniques and technologies to improve
procedural success may have an impact on prognosis. A
randomized trial is now needed.
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